Holds 2 active US DMFs for exatecan, filing since 2026. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for exatecan, filing since 2026. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for exatecan, filing since 2025. Its 2024 FDA inspection closed as NAI.
Holds one active US DMF for exatecan, filing since 2022. Its GMP is recognised in 1 market.
Holds one active US DMF for exatecan, filing since 2024.
Holds one active US DMF for exatecan, filing since 2022.
Holds one active US DMF for exatecan, filing since 2023.
Holds one active US DMF for exatecan, filing since 2022.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for exatecan and what filings they hold.
Chat with Fred, your AI analyst